Background: Sclerosing encapsulating peritonitis (SEP) is a serious complication seen in patients on long-term continuous ambulatory peritoneal dialysis (CAPD). We have previously reported that mesothelial cells in effluent dialysate significantly increased in size as the duration of CAPD progressed. In this study, we investigated the relationship between mesothelial cytology, histopathology of the peritoneum, and clinical outcomes of 34 CAPD patients. Methods: When peritoneal dialysis catheters were inserted (n = 7) or removed (n = 27), a peritoneal biopsy was performed and results compared with mesothelial cytology in effluent dialysate. Results: A significant positive correlation was noted between the duration of CAPD and the surface area of peritoneal mesothelial cells (r = 0.721, p < 0.0001). The surface area of mesothelial cells in peritoneal sclerosis (n = 9; 584 ± 97 µm2) was significantly greater than in peritoneal fibrosis (n = 14; 389 ± 26 µm2, p < 0.05), pathologic acute peritonitis (n = 3; 223 ± 10 µm2, p < 0.005), and normal peritoneum (n = 7; 247 ± 12 µm2, p < 0.001). The surface area in sclerosing peritonitis (n = 1; 1,200 µm2) was greater than that of all the others. Giant cells were found in the 1 case with sclerosing peritonitis and in 3 of 9 cases with peritoneal sclerosis, although they were found in only 1 of 14 patients with peritoneal fibrosis and in none of those with pathologic acute peritonitis or normal peritoneum. As the surface area of mesothelial cells increased to more than 400 µm2 and giant cells appeared in the effluent, the frequency of peritoneal sclerosis and/or clinical SEP increased. Conclusion: An increase in the mesothelial cell surface area and the emergence of giant cells in the effluent indicate advanced peritoneal histopathology, and may be useful indicators to determine appropriate timing of discontinuation of CAPD to prevent the development of SEP.

Keywords:
Continuous ambulatory peritoneal dialysis, Effluent dialysate, Mesothelial cell, Peritoneal histopathology, Peritoneal sclerosis, Sclerosing encapsulating peritonitis
1.
Yamamoto T, Izumotani T, Otoshi T, Kim M: Morphological studies of mesothelial cells in CAPD effluent and their clinical significance. Am J Kidney Dis 1998;32:946–952.
2.
Pollock CA, Ibels LS, Eckstein RP, Graham JC, Caterson RJ, Mahony JF, Sheil AGR: Peritoneal morphology on maintenance dialysis. Am J Nephrol 1989;9:198–204.
3.
Dobbie JW: Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992;12:14–27.
4.
Jörres A, Ludat K, Sander K, Dunkel K, Lorenz F, Keck H, Frei U, Gahl GM: The peritoneal fibroblast and the control of peritoneal inflammation. Kidney Int 1996;50(suppl 56):S22–S27.
5.
Mateijsen MA, van der Wal AC, Hendriks PMEM, Zweers MM, Mulder J, Struijk DG, Krediet RT: Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999;19:517–525.
6.
Nomoto Y, Kawaguchi Y, Sakai S, Hirano H, Kubo H, Ohira S, Honma S, Yamagata K, Miura Y, Kimura Y, Kuriyama S, Hara S, Hamada C, Sanaka T, Nakao T, Honda M, Yokota S, Suga T, Mori N, Shimomura A, Kim M, Imada A, Tanaka R, Kawanishi H, Edakuni S, Fukui H, Nakamoto M, Kurokawa K: Sclerosing encapsulating peritonitis (SEP) in patients on continuous ambulatory peritoneal dialysis – Definition, diagnosis and treatment recommendations, 1997 update. J Jpn Soc Dial Ther 1998;31:303–311.
7.
Rigby RJ, Hawley CM: Sclerosing peritonitis: The experience in Australia. Nephrol Dial Transplant 1998;13:154–159.
8.
Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K: Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: A report of the Japanese sclerosing encapsulating peritonitis study group. Am J Kidney Dis 1996;28:420–427.
9.
Hendriks PMEM, Ho-dac-Pannekeet MM, ban Gullik TM, Struijk DG, Phoa SSKS, Sie LH, Kox CS, Krediet RT: Peritoneal sclerosis in chronic peritoneal dialysis patients: Analysis of clinical presentation, risk factors and peritoneal transport kinetics. Perit Dial Int 1997;17:136–143.
10.
Fernandez de Castro M, Selgas R, Jimenez C, Bajo MA, Martinez V, Romero JR, Alvaro F, Vara F: Cell populations present in the nocturnal peritoneal effluent of patients on continuous ambulatory peritoneal dialysis and their relationship with peritoneal function and incidence of peritonitis. Perit Dial Int 1994;14:265–270.
11.
Twardowski ZJ: The fast peritoneal equilibration test. Semin Dial 1990;3:141–142.
12.
Hare CM: Radiological view of sclerosing peritonitis. Nephrol Dial Transplant 1999;14:497–498.
13.
Oules R, Challah S, Brunner FP: Case control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988;3:66–69.
14.
Kawaguchi Y: Present status of CAPD in Japan. Am J Kidney Dis 1998;32:xlix-lii.
15.
Lo WK, Chan KT, Leung AC, Pang SW, Tse CY: Sclerosing peritonitis complicating prolonged use of chlorhexidine in alcohol in the connection procedure for continuous ambulatory peritoneal dialysis. Perit Dial Int 1991;11:166–172.
16.
Selgas R, Fernandez de Castro M, Viguer JM, Burgos E, Bajo MA, Carcamo C, Vara F: Transformed mesothelial cells in patients on CAPD for medium- to long-term periods. Perit Dial Int 1995;15:305–311.
17.
Dobbie JW: New concepts in molecular biology and ultrastructural pathology of the peritoneum: Their significance for peritoneal dialysis. Am J Kidney Dis 1990;15:97–109.
18.
Yang AH, Chen JY, Lin YP, Haung TP, Wu CW: Peritoneal dialysis solution induces apoptosis of mesothelial cells. Kidney Int 1997;51:1280–1288.
19.
Minquil MCJ, Imholz ALT, Struijk DG, Krediet RT: Does impaired transcellular water transport contribute to net ultrafiltration failure during CAPD? Perit Dial Int 1995;15:42–48.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.